Development and Challenges of Antimicrobial Peptides for Therapeutic Applications.

Chen CH, Lu TK. · 2020

Read Development and Challenges of Antimicrobial Peptides for Therapeutic Applications. by Chen CH, Lu TK. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7168295.txt.

Introduction

Chen and Lu review antimicrobial peptides as candidate drugs and the obstacles to using them, in Antibiotics. More than 3,000 such peptides, part of natural immune defences across species, have been discovered. Only seven have won United States approval, mostly as topical treatments, though some are injected for severe infections.

All approved examples came from Gram-positive soil bacteria, and 98% of known peptides come from natural sources such as frog skin. Problems include instability in the body and toxicity to human cells. The authors compare approved drugs with the wider peptide catalogue on structure and mechanism, aiming to guide rational design of peptides that keep the bacteria-killing power while shedding the flaws.

Catalog record

CREATORChen CH, Lu TK.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE59 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7168295

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Development and Challenges of Antimicrobial Peptides for Therapeutic Applications By Charles H Chen, Timothy K Lu Published in: Antibiotics DOI: 10.3390/antibiotics9010024 ABSTRACT Abstract More than 3000 antimicrobial peptides (AMPs) have been discovered, seven of which have been approved by the U.S. Food and Drug Administration (FDA). Now commercialized, these seven peptides have mostly been utilized for topical medications, though some have been injected into the body to treat severe bacterial infections. To understand the translational potential for AMPs, we analyzed FDA-approved drugs in the FDA drug database. We examined their physicochemical properties, secondary structures, and mechanisms of action, and compared them with the peptides in the AMP database. All FDA-approved AMPs were discovered in Gram-positive soil bacteria, and 98% of known AMPs also come from natural sources (skin secretions of frogs and toxins from different species). However, AMPs can have undesirable properties as drugs, including instability and toxicity. Thus, the design and construction of effective AMPs require an understanding of the mechanisms of known peptides and their effects on the human body. This review provides an overview to guide the development of AMPs that can potentially be used as antimicrobial drugs. Keywords: antimicrobial peptides, antibiotics, antibiotic resistance, rational protein design, peptide therapeutics, FDA-approved peptides 1. INTRODUCTION In the past several decades, multidrug-resistant bacteria have rapidly spread, causing increases in nosocomial infections and in-hospital mortality, and posing a threat to global health [1,2,3,4]. Moreover, the discovery of new classes of antibiotics has slowed down since 1987 [5,6]. The lack of new discoveries might be prompted by the conservative way we have searched for antibiotics, or this field may be saturated [5,6]; in other words, we may have already discovered many of the large natural structures that have antimicrobial activity. With the rise of antibiotic resistance, our last lines of effective antibiotics are failing [7,8,9]. Antimicrobial peptides (AMPs), a ubiquitous part of the innate immune defense in all classes of life, have been widely studied and show potential as small molecule antibiotics [10,11,12]. 2. FDA DRUG APPROVALS AND DATABASES More than 3000 AMPs have been reported and characterized [13], but in their natural state, most are not suitable as drugs for human medicine. In fact, many of them failed prior to or during clinical trials [14]. To understand this problem, we looked into peptide drugs that have been approved by the U.S. Food and Drug Administration (FDA). Using the Therapeutic Proteins Database [THPdb, a subset of the FDA database (Drugs@FDA)], we analyzed all the peptide therapeutics so far approved by the FDA [15]. This database has a total of 852 peptide and protein therapeutics. Of these, 239 have been validated while the others are their derivatives and/or similar ingredients for therapeutics, and 27 of the 239 are small peptides (fewer than 50 amino acids). Six of the small peptides are AMPs: gramicidin D, daptomycin, vancomycin, oritavancin, dalbavancin, and telavancin (Figure 1). [Figure: Chemical structures of seven FDA-approved AMPs. From upper left to bottom right: gramicidin (linear peptide; pore-forming peptide), daptomycin (cyclic lipopeptide; membrane-lytic peptide), colistin (cyclic lipopeptide; membrane-lytic peptide), vancomycin (lipoglycopeptide; inhibitor of cell wall synthesis), oritavancin (lipoglycopeptide; dual-mechanism: membrane-lytic peptide and inhibitor of cell wall synthesis), dalbavancin (lipoglycopeptide; inhibitor of cell wall synthesis), and telavancin (lipoglycopeptide; dual-mechanism: membrane-lytic peptide and inhibitor of cell wall synthesis). MoA indicates “mechanism of action”. T1/2 indicates the elimination half-life.] Gramicidin D, first isolated from the soil bacterium Bacillus brevis and characterized in 1941, is a heterogeneous mixture of three pore-forming peptides: gramicidins A (80%), B (5%), and C (15%) [16,17,18,19,20,21]. Gramicidin D was approved by the FDA in 1955 as a constituent in Neosporin® [22], a triple antibiotic ointment for treating bacterial conjunctivitis. Daptomycin is a 13-residue cyclic lipopeptide antibiotic that binds onto the bacterial cell membrane, aggregates, and disrupts the membrane [23,24]. Daptomycin (also known as LY146032 [25]) and its derivative Cubicin (manufactured by Cubist Pharmaceuticals, now Merck & Co.) were approved in 2003 by the FDA to treat or prevent infectious diseases [26]. Cubicin and its new formulation Cubicin RF, which can be directly injected into the body, are antibiotics used for the treatment of complicated skin and skin structure infections (cSSSI) and Staphylococcus aureus bloodstream infections. Oritavancin, dalbavancin (formerly BI-397), and telavancin are small lipoglycopeptide antibiotics derived from vancomycin (approved by the FDA as an oral solution in 1983). These lipoglycopeptides are more potent and bactericidal than their prototype vancomycin, and they are effective against vancomycin-resistant bacteria. They inhibit bacterial cell wall formation [27,28], and telavancin and oritavancin also disrupt bacterial cell membranes and affect membrane permeability [29,30]. Similar to Cubicin, the therapeutic products Orbactiv (oritavancin), Dalvance (dalbavancin), and Vibativ (telavancin) are being used for injection against cSSSI caused by S. aureus, as well as other Gram-positive bacterial infections, and were approved by the FDA in 2014, 2014, and 2009, respectively. One FDA-approved AMP is not mentioned in the THPdb. Colistin, also known as polymyxin E, is an antibacterial cyclic lipopeptide that was approved by the FDA in 1962 and is manufactured by Endo Pharmaceuticals, Inc, Malvern, Pennsylvania, U.S.A. as the product Coly-Mycins (colistin sulfate). Colistin is composed of 10 amino acids (sequence: KTKKKLLKKT; MW = 1145) and one fatty acid (6-methyl octanoic acid). Six of the constituent amino acids are positively charged (e.g., lysine), while the hydrophobic content is 20%. Colistin is active against several Gram-negative bacteria, e.g., Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp. Peptide stability is a key requirement for the use of peptides as drugs [31,32,33,34]. Nevertheless, the hormone insulin and its analogs, which are among the most well-known peptides, have a short elimination half-life (4-6 min) in the bloodstream. Insulin was the first genetically engineered peptide hormone and was approved by the FDA in 1982 for the treatment of diabetes [35,36]. The elimination half-life of FDA-approved AMPs is much longer than that of insulin [13,31,32,33,34]. Daptomycin, oritavancin, dalbavancin, telavancin, and colistin have elimination half-lives of 8–9 h, 14 days, 8 h, 195.4 h, and 5 h, respectively (that of gramicidin has not been determined). More broadly, the average elimination half-life of FDA-approved new drugs is 50 h (median = 9 h), and of FDA-approved small peptides (less than 50 amino acids) for therapeutic use is 37 h (median = 3 h) (Figure 2). Thus, most of the FDA-approved peptides included in this analysis are stable in vivo, probably because those that are not biologically stable are unsuitable as drugs [31,32,33,34]. More rigid peptide structures may extend the elimination half-life [37,38,39]. For example, cyclic lipopeptides (e.g., daptomycin and colistin) and cyclic lipoglycopeptides (e.g., vancomycin, oritavancin, dalbavancin, and telavancin) are more stable than their linear counterparts [40]. In addition, introducing non-canonical amino acids into the peptide sequence can prevent biological degradation by proteases and extend the elimination half-life [41]. [Figure: The elimination half-life (hours) of all FDA-approved drugs (509 validated molecules out of 555 molecules; black) and FDA-approved small peptides (54 validated molecules out of 57 molecules; gray). The FDA-approved drugs also include the FDA-approved small peptides. The FDA-approved small peptides are summarized in Table 1. The raw data (submission classification: Type 1—New Molecular Entity between January 1999 and December 2019) were collected from Drugs@FDA (http://www.fda.gov/drugsatfda).] 3. ANTIMICROBIAL PEPTIDE DATABASE To date, only seven small AMPs have been approved

Read the complete text